A few months after its deal with Amgen, San Diego-based biotech Plexium has inked a deal with another Big Pharma – this time, it’s AbbVie.
While Amgen’s deal focused on the cancer space, AbbVie hopes to use Plexium’s “agnostic” targeted protein degradation (TPD) platform to screen for new therapies for...
